留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

黄芪甲苷抑制U937巨噬细胞CCL18表达及其作用机制研究

底雪梅,  袁曜晖,  张超,  高越

downloadPDF
文章导航 > 药学实践与服务  > 2019 >  37(1): 32-36,41
底雪梅, 袁曜晖, 张超, 高越. 黄芪甲苷抑制U937巨噬细胞CCL18表达及其作用机制研究[J]. 药学实践与服务, 2019, 37(1): 32-36,41. doi: 10.3969/j.issn.1006-0111.2019.01.008
引用本文: 底雪梅, 袁曜晖, 张超, 高越. 黄芪甲苷抑制U937巨噬细胞CCL18表达及其作用机制研究[J]. 药学实践与服务, 2019, 37(1): 32-36,41. doi: 10.3969/j.issn.1006-0111.2019.01.008
shu
DI Xuemei, YUAN Yaohui, ZHANG Chao, GAO Yue. Research on the effect and mechanism of astragalus Ⅳ(AS-Ⅳ) on the expression of CCL18 in U937 macrophages[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 32-36,41. doi: 10.3969/j.issn.1006-0111.2019.01.008
Citation: DI Xuemei, YUAN Yaohui, ZHANG Chao, GAO Yue. Research on the effect and mechanism of astragalus Ⅳ(AS-Ⅳ) on the expression of CCL18 in U937 macrophages[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 32-36,41. doi: 10.3969/j.issn.1006-0111.2019.01.008
shu

黄芪甲苷抑制U937巨噬细胞CCL18表达及其作用机制研究

doi: 10.3969/j.issn.1006-0111.2019.01.008
  • 1.

    同济大学附属第一妇婴保健院, 上海 201204

  • 2.

    山东中医药大学药学院, 山东 济南 2503553

  • 3.

    海军军医大学药学院实验教学中心, 上海 200433

基金项目: 上海市科委产学研医结合项目（15DZ1900102）

Research on the effect and mechanism of astragalus Ⅳ(AS-Ⅳ) on the expression of CCL18 in U937 macrophages

  • 1.

    First Maternity and Infant Hospital, Tongji University, Shanghai 201204, China

  • 2.

    School of Pharmaceutical Sciences, Shandong University of Traditional Chinese Medicine, Jinan 250355, China

  • 3.

    Experimental and Teaching Center, School of Pharmacy, Naval Medical University, Shanghai 200433, China

  • 摘要: 目的 研究黄芪甲苷（AS-Ⅳ）抑制组织细胞淋巴瘤细胞U937，刺激巨噬细胞分泌肿瘤促进因子CCL18表达及其作用机制。 方法 考察黄芪甲苷对白细胞介素4（IL-4）刺激巨噬细胞CCL18表达的影响；实时PCR检测CCL18 mRNA表达水平；采用酶联免疫吸附检测（Elisa）法测定CCL18蛋白水平；流式细胞仪检测白细胞介素4受体（IL-4R）的表达水平；Elisa法检测信号传导及转录激活因子6（STAT6）磷酸化水平；采用Z″-LYTETM激酶检测法检测Janus激酶（JAK）活性。 结果 黄芪甲苷能显著抑制IL-4诱导的U937巨噬细胞CCL18表达上调，且呈明显的量效依赖性，但对IL-4受体组成亚基表达影响不显著；黄芪甲苷可抑制STAT6的磷酸化，但作用小于AS1517499；黄芪甲苷可抑制JAK1，JAK3和酪氨酸激酶2（TYK2）的活性。 结论 黄芪甲苷可抑制IL-4刺激的U937巨噬细胞CCL18的表达。其作用途径之一可能是通过抑制JAK激酶活性，引起STAT6的转录活性下调，从而抑制CCL18基因表达。
    Abstract: Objective To investigate the effect and mechanism of astragalus Ⅳ(AS-Ⅳ) on the expression of CCL18 in U937 macrophages. Methods The expression of CCL18 mRNA was detected by real time PCR. The expression of CCL18 protein was assessed by Elisa. The expression of IL-4 receptor was measured by flow cytometry. The STAT6 phosphorylation was measured by Elisa. The activity of JAK kinase was detected by Z″-LYTETM kinase assay. Results AS-Ⅳ significantly down-regulated the expression of CCL18 in U937 macrophages stimulated by IL-4 with a dose-dependent manner. However, AS-Ⅳ had no significant effect on IL-4 receptor subunit expression. The STAT6 phosphorylation was inhibited by AS-Ⅳ, but the effect was less than AS1517499; the activity of JAK1, JAK3 and TYK2 kinase were inhibited by AS-Ⅳ. Conclusion AS-Ⅳ could inhibit the expression of CCL18 in U937 macrophages stimulated by IL-4. One of the suggested mechanisms was due to inhibition of JAK kinase activity, which caused STAT6 transcriptional activity down and inhibited CCL18 gene expression.
  • [1] RAGHU G,WEYCKER D,EDELSBERG J,et al. Incidence and prevalence of idiopathic pulmonary fibrosis[J]. Am J Respir and Crit Care Med,2006,174(7):810-816.
    [2] 蒋云峰.黄芪桃红汤治疗特发性肺纤维化24例[J].吉林中医药,2003,23(11):14.
    [3] 李丽君,范盎然,葛东宇,等.黄芪当归对药对特发性肺纤维化小鼠生存状况及组织修复相关基因表达水平的影响[J].环球中医药,2015,8(12):1441-1445.
    [4] 李红,王胜,沈明霞,等.黄芪甲苷对特发性肺纤维化模型大鼠肺组织碱性成纤维细胞生长因子(bFGF)表达的影响[J].西部中医药,2015,28(12):21-24.
    [5] 李红,沈明霞,谢海彬,等.黄芪甲苷对特发性肺纤维化模型大鼠肺组织CD34表达的影响[J].西部中医药,2015,28(9):6-10.
    [6] PRASSE A,PECHKOVSKY D V,TOEWS G B,et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis[J]. Arthriti Rheumat,2007,56(5):1685-1693.
    [7] CAI M,BONELLA F,HE X,et al. CCL18 in serum,BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases[J]. Respir Med,2013,107(9):1444-1452.
    [8] PRASSE A,PROBST C,BARGAGLI E,et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Me,2009,179(8):717-723.
    [9] HIESHIMA K,IMAI T,BABA M,et al. A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes,but not for monocytes[J]. J Immunol,1997,159(3):1140-1149.
    [10] Kodelja V,Müller C,Politz O,et al. Alternative macrophage activation-associated CC-chemokine-1,a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern.[J]. J Immunol,1998,160(3):1411-1418.
    [11] PRASSE A,PECHKOVSKY D V,TOEWS G B,et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18[J]. Am J Respi Crit Care Med,2006,173(7):781-792.
    [12] PECHKOVSKY D V,PRASSE A,KOLLERT F,et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction[J]. Clin Immunol,2010,137(1):89-101.
    [13] ANDO M,MIYAZAKI E,FUKAMI T,et al. Interleukin-4-producing cells in idiopathic pulmonary fibrosis:an immunohistochemical study[J]. Respirology,1999,4(4):383-391.
    [14] WALLACE W A,HOWIE S E. Immunoreactive interleukin 4 and interferon gamma expression by type Ⅱ alveolar epithelial cells in interstitial lung disease[J].J Pathol,1999,187(4):475-480.
    [15] SCHUTYSER E,RICHMOND A,DAMME J V. Involvement of CC chemokine ligand 18(CCL18) in normal and pathological processes[J]. J Leuk Biol,2005,78(1):14-26.
    [16] ATAMAS S P,LUZINA I G,CHOI J,et al. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts[J]. Am J Respir Cell Mol Biol,2003,29(6):743-749.
    [17] LUZINA I G,PAPADIMITRIOU J C,ANDERSON R,et al. Induction of prolonged infiltration of T lymphocytes and transient T lymphocyte dependent collagen deposition in mouse lungs following adenoviral gene transfer of CCL18[J]. Arthr Rheum,2006,54(8):2643-2655.
    [18] LUZINA I G,KEEGAN A D,HELLER N M,et al. Regulation of inflammation by interleukin-4:a review of "alternatives"[J]. J Leuk Biol,2012,92(4):753-764.
  • [1] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
    [2] 冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军.  雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
    [3] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 1-6. doi: 10.12206/j.issn.2097-2024.202312054
    [4] 姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量.  巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202305011
    [5] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [6] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3365
  • HTML全文浏览量:  758
  • PDF下载量:  911
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-07-06
  • 修回日期:  2018-12-31

黄芪甲苷抑制U937巨噬细胞CCL18表达及其作用机制研究

doi: 10.3969/j.issn.1006-0111.2019.01.008
  • 1. 同济大学附属第一妇婴保健院, 上海 201204
  • 2. 山东中医药大学药学院, 山东 济南 2503553
  • 3. 海军军医大学药学院实验教学中心, 上海 200433
    • 基金项目:  上海市科委产学研医结合项目（15DZ1900102）
  • 收稿日期: 2018-07-06
  • 修回日期: 2018-12-31

摘要: 目的 研究黄芪甲苷（AS-Ⅳ）抑制组织细胞淋巴瘤细胞U937，刺激巨噬细胞分泌肿瘤促进因子CCL18表达及其作用机制。 方法 考察黄芪甲苷对白细胞介素4（IL-4）刺激巨噬细胞CCL18表达的影响；实时PCR检测CCL18 mRNA表达水平；采用酶联免疫吸附检测（Elisa）法测定CCL18蛋白水平；流式细胞仪检测白细胞介素4受体（IL-4R）的表达水平；Elisa法检测信号传导及转录激活因子6（STAT6）磷酸化水平；采用Z″-LYTETM激酶检测法检测Janus激酶（JAK）活性。 结果 黄芪甲苷能显著抑制IL-4诱导的U937巨噬细胞CCL18表达上调，且呈明显的量效依赖性，但对IL-4受体组成亚基表达影响不显著；黄芪甲苷可抑制STAT6的磷酸化，但作用小于AS1517499；黄芪甲苷可抑制JAK1，JAK3和酪氨酸激酶2（TYK2）的活性。 结论 黄芪甲苷可抑制IL-4刺激的U937巨噬细胞CCL18的表达。其作用途径之一可能是通过抑制JAK激酶活性，引起STAT6的转录活性下调，从而抑制CCL18基因表达。

English Abstract

底雪梅, 袁曜晖, 张超, 高越. 黄芪甲苷抑制U937巨噬细胞CCL18表达及其作用机制研究[J]. 药学实践与服务, 2019, 37(1): 32-36,41. doi: 10.3969/j.issn.1006-0111.2019.01.008
引用本文: 底雪梅, 袁曜晖, 张超, 高越. 黄芪甲苷抑制U937巨噬细胞CCL18表达及其作用机制研究[J]. 药学实践与服务, 2019, 37(1): 32-36,41. doi: 10.3969/j.issn.1006-0111.2019.01.008
shu
DI Xuemei, YUAN Yaohui, ZHANG Chao, GAO Yue. Research on the effect and mechanism of astragalus Ⅳ(AS-Ⅳ) on the expression of CCL18 in U937 macrophages[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 32-36,41. doi: 10.3969/j.issn.1006-0111.2019.01.008
Citation: DI Xuemei, YUAN Yaohui, ZHANG Chao, GAO Yue. Research on the effect and mechanism of astragalus Ⅳ(AS-Ⅳ) on the expression of CCL18 in U937 macrophages[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 32-36,41. doi: 10.3969/j.issn.1006-0111.2019.01.008
shu

    全文HTML

参考文献 (18)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计